DE69912477D1 - Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs - Google Patents

Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Info

Publication number
DE69912477D1
DE69912477D1 DE69912477T DE69912477T DE69912477D1 DE 69912477 D1 DE69912477 D1 DE 69912477D1 DE 69912477 T DE69912477 T DE 69912477T DE 69912477 T DE69912477 T DE 69912477T DE 69912477 D1 DE69912477 D1 DE 69912477D1
Authority
DE
Germany
Prior art keywords
tamoxife
endocrin
therapy
treatment
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69912477T
Other languages
English (en)
Other versions
DE69912477T2 (de
Inventor
H Safe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of DE69912477D1 publication Critical patent/DE69912477D1/de
Application granted granted Critical
Publication of DE69912477T2 publication Critical patent/DE69912477T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
DE69912477T 1998-12-21 1999-12-21 Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs Expired - Fee Related DE69912477T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US217780 1994-03-25
US09/217,780 US6136845A (en) 1998-12-21 1998-12-21 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl PCDFs
PCT/US1999/030554 WO2000037065A2 (en) 1998-12-21 1999-12-21 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs

Publications (2)

Publication Number Publication Date
DE69912477D1 true DE69912477D1 (de) 2003-12-04
DE69912477T2 DE69912477T2 (de) 2004-08-19

Family

ID=22812479

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912477T Expired - Fee Related DE69912477T2 (de) 1998-12-21 1999-12-21 Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Country Status (9)

Country Link
US (1) US6136845A (de)
EP (1) EP1140047B1 (de)
JP (1) JP2002532546A (de)
AT (1) ATE252896T1 (de)
AU (1) AU772920B2 (de)
CA (1) CA2356624A1 (de)
DE (1) DE69912477T2 (de)
ES (1) ES2207981T3 (de)
WO (1) WO2000037065A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
WO2005035517A1 (en) * 2003-10-14 2005-04-21 Council Of Scientific And Industrial Research (3r, 4r)-trans-3,4-diarylchroman derivatives with estrogenic activity
CN1318411C (zh) * 2005-03-21 2007-05-30 中国海洋大学 氢化轮枝霉酮类化合物及其制备方法和用途
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
JP5476587B2 (ja) * 2007-10-26 2014-04-23 アカディア ファーマシューティカルズ,インコーポレーテッド エストロゲン受容体に対して活性を有する縮合化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5516790A (en) * 1989-01-23 1996-05-14 Texas A&M University System Technology Licensing Office Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
CA2356624A1 (en) 2000-06-29
AU2376600A (en) 2000-07-12
DE69912477T2 (de) 2004-08-19
AU772920B2 (en) 2004-05-13
WO2000037065A3 (en) 2000-09-14
US6136845A (en) 2000-10-24
WO2000037065A2 (en) 2000-06-29
EP1140047A2 (de) 2001-10-10
ATE252896T1 (de) 2003-11-15
ES2207981T3 (es) 2004-06-01
EP1140047B1 (de) 2003-10-29
JP2002532546A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE69812159T2 (de) Derivate des adamantan
PT1200412E (pt) Agentes anti-proliferativos de imidazole
DE50310516D1 (de) Fredericamycin-derivate
SE9903998D0 (sv) New compounds
WO2003087831A3 (en) Proteins involved in breast cancer
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
DE60216233D1 (en) Carbolinderivate
HK1051324A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity.
SE9900961D0 (sv) Novel compounds
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
SE9802208D0 (sv) Novel compounds
AU3392901A (en) Proteins
DE69912477D1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
PT1206256E (pt) Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
DE50211672D1 (de) Urokinase-inhibitoren
ATE333277T1 (de) Behandlung von dyskinesie
PL365279A1 (en) Biotin-derivates and their conjugates with chelating agents
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
RS16804A (en) Use of 4-pyridylmethylphthalazines for cancer treatment

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee